Background and Aim: Although the clinicopathological significance of the expres-
| INTRODUCTION
Binding of programmed death-1 (PD-1) and its ligands-programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2)-on tumor or immune cells can inhibit cytotoxic T-cell responses, allowing tumor cells to evade immune detection. 1 Clinical trials of anti-PD-1/PD-L1 antibodies have reported a high response rate and significantly improved overall survival in several malignancies. [2] [3] [4] PD-L1 is constitutively expressed in several tumor tissues, including gastric cancer. [5] [6] [7] Overexpression of PD-L1 in tumor tissue has been reported to be associated with poor overall survival and good response to anti-PD-L1 antibody treatment. 8, 9 Serum PD-L1 level was significantly higher in patients with malignancies than in healthy individuals. [10] [11] [12] Zheng et al 10 reported the association of serum PD-L1 level with prognosis in patients with advanced gastric cancer.
However, their series included a small number of patients, and they did not carry out multivariate analysis to evaluate the prognostic impact of serum PD-L1 level. Takahashi et al 12 also reported the correlation of high serum PD-L1 with shorter overall survival in patients with unresectable or recurrent advanced gastric cancer.
However, they did not analyze patients with surgically treated gastric cancer.
Therefore, the present study evaluated the clinicopathological and prognostic significance of serum PD-L1 level in patients with surgically treated gastric cancer. The main focus was to evaluate the prognostic significance of preoperative serum PD-L1 level. (vii) Using a microplate reader set to 450 nm, optical density of each well was determined, and wavelength correction was set to 540 nm.
| MATERIALS AND METHODS

| Patients
| Serum biomarker analysis
The inflammatory marker, C-reactive protein (CRP), albumin, and hemoglobin were also analyzed before surgery to evaluate their association with serum PD-L1 level. White blood cell, neutrophil, lymphocyte, and eosinophil counts were also examined. Cutoff values were determined in accordance with the institutional standards for white blood cell count (9000 cells/mm 3 ) and CRP levels (0.3 mg/mL).
| Statistical analysis
Continuous data from patients were expressed as mean AE SD. Comparisons between unpaired groups for these variables were conducted using the Mann-Whitney U test. Differences in the distribution of two variables were evaluated using Fisher's exact test or v 2 test. Clinicopathological data were analyzed using logistic regression analysis to evaluate the association with serum PD-L1
level. Survival curves were calculated using the Kaplan-Meier method and compared using log-rank test. Significant predictors identified using univariate analysis were assessed using multivariate analysis with the Cox proportional hazards model. All statistical analyses were carried out using EZR statistical software. 14 Statistical significance was defined as P < .05.
| RESULTS
| Correlation of clinical characteristics, biomarkers, TNM stage, and pathological characteristics with serum PD-L1 level
In terms of clinical variables, serum PD-L1 level was positively correlated with age (P = .01) and lymph node metastases (P = .04) but was not associated with depth of tumor, tumor size, and histological differentiation (Table 1) . Such a tendency was very similar among stage I/II/III patients (Table S1 ). There were no significant differences between serum PD-L1 levels in relation to tumor stage (Figure 1 ).
| Association of serum PD-L1 level with other serum biomarkers
Serum PD-L1 level positively correlated with high CRP (P < .01), low albumin (P < .01) levels and CA19-9 levels (P < .01; Table 2 ). Such a tendency was very similar among stage I/II/III patients (Table S2 ). was 50.4 AE 22.5 pg/mL; therefore, we fixed the cutoff value for serum PD-L1 level at 50 pg/mL for further analyses.
| Multivariate analysis of the association of high serum PD-L1 level with age and CA19-9, CRP, and albumin levels
Based on the univariate analyses shown in Tables 1 and 2, contribution of the three serum biomarkers (CRP, CA19-9, and albumin) to high serum PD-L1 level (>50 pg/mL) was evaluated. Multivariate analysis showed that CA19-9 and CRP, or CA19-9 and albumin, were associated with high serum PD-L1 level (P < .05, P = .05; Table 3 ). Such a tendency was very similar among stage I/II/III patients (Table S3 ).
| Overall survival and progression-free survival curves according to serum PD-L1 level
Patients in the high serum PD-L1 group showed significantly poorer survival than those in the low serum PD-L1 group (P < .05, Figure 2). Although this tendency was not confirmed in patients with stage I or II gastric cancer, a similar tendency was confirmed in patients with stage III or IV gastric cancer (Figure 3 ). In the multivariate analysis, gender, serum PD-L1 level, and tumor stage were independent risk factors for poor overall survival (Table 4 ). In the multivariate analysis, such a tendency was very similar focusing on stage I/II/III patients only (Table S4) .
A variety of recurrent tumors was observed among 129 patients with stage I/II/III cancer. The recurrent patterns included seven for liver metastases, three for lung metastases, six for peritoneal metastases, three for lymph node metastases, and one for local recurrence.
Although serum PD-L1 levels of the patients were higher in the recurrent group than in the non-recurrent group, the difference was not statistically significant (P = .09, Figure S1 ). Moreover, no significant differences were observed among recurrent patterns.
| DISCUSSION
In the present study, preoperative serum PD-L1 level was significantly associated with age and CA19-9, CRP, and albumin levels but not with tumor stage. With a cutoff value of 50 pg/mL, preoperative high serum PD-L1 level was an independent risk factor for the poor overall survival of patients with gastric cancer.
Among the serum biomarkers, CRP, albumin, and CA19-9 were independent risk factors for increased serum PD-L1 level. Some inflammatory cytokines, such as interleukin-6, may affect such association of CRP level with serum PD-L1 level. Although Xu et al have reported that high interleukin-6 (IL-6) level in patients with prostate cancer was associated with the expression of PD-L1 in prostate cancer tissues, 15 the mechanism of high serum PD-L1 levels is unclear.
Average serum PD-L1 level has been reported to be much higher in healthy volunteers aged >70 years than in those aged <70 years. 16 Our present data confirmed this tendency. Because human immunological potency decreases with age, 16 serum PD-L1 level may be negatively correlated with immunological status. Based on these findings, age and IL-6 and serum PD-L1 levels may be correlated with the poor overall survival of patients with cancer. Using the same ELISA kit as that used in the present study, Chen et al 18 reported that the median serum PD-L1 level in healthy controls was 48.15 pg/mL, which is very similar to the median serum PD-L1 level reported in our series of patients with gastric cancer. Therefore, we suspect that there is no statistically significant difference in serum PD-L1 level between healthy controls and patients with gastric cancer.
Another limitation was that there were no paired serum samples of these patients after surgery. Therefore, we could not compare serum PD-L1 level between before and after surgery. protein, may have some interaction with the anti-PD-L1 antibody.
Further prospective observation study is required to monitor fluctuations in serum PD-L1 level during anti-PD-L1 antibody treatment, which will further clarify the clinical significance of serum PD-L1 level in patients with gastric cancer.
In conclusion, high serum PD-L1 level was found to be an independent prognostic factor in patients with surgically treated gastric cancer. Because serum PD-L1 may reflect the systemic immune checkpoint pathway status, serum PD-L1 level seems to be a convenient prognostic serum biomarker.
